Search

everythinglearnresearchcommunity

for

Search:↓

Gene variation affects prostate issues and hair loss.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Large prostate patients more likely to have hair loss.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Early baldness in men may indicate a higher risk of prostate cancer.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

Men who start losing hair at 20 may have a higher chance of getting prostate cancer later.

Early baldness increases prostate cancer risk, radiotherapy and surgery have similar second cancer rates, and ALA may reduce prostate cancer risk.

PSA is best for detecting prostate cancer recurrence and evaluating treatment response.

Men, especially older ones with health issues like prostate cancer, may have worse COVID-19 outcomes and could benefit from therapies targeting male hormones.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Prostate cells have proteins that bind to specific hormones, which can increase protein production when activated by these hormones.

New method finds genetic links between Type 2 Diabetes and Prostate Cancer not seen before.

CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.

Estradiol and castration reduced prostate cancer development in rats when applied at early stages, but were ineffective after cancer was established.

Prostasin has two roles in skin: one for normal skin development without needing activation, and another for proper hair growth that requires activation.

Baldness at age 40 is not linked to a higher risk of aggressive prostate cancer.

Certain genetic variants increase the risk of aggressive prostate cancer.

Metformin may lower PSA levels, possibly affecting prostate cancer development.

Early balding at 40 increases prostate cancer risk.

Platelet-rich plasma can improve erectile function in older individuals by reducing prostate enlargement.

Testosterone replacement therapy, especially intramuscular, raises PSA levels, but no overall link between PSA and testosterone was found except in non-BPH patients.

A woman's scalp condition improved with specific ointment after a hair piece caused skin issues.

PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Computational methods help design drugs targeting prostate cancer proteins.

Adding hormone therapy to radiation improves survival for high-risk prostate cancer recurrence but has side effects.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.